SynuCa Therapeutics
PrivateLast Round
Follow-on Offering
Mar 2, 2026
Total Funding Raised
$2.01M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
SynuCa Therapeutics operates in Healthcare & Life Sciences and is based in Copenhagen. Its latest recorded funding round was a Follow-on Offering round in March 2026.
SynuCa Therapeutics is a drug discovery company that develops small molecule therapies intended to address Parkinson's disease and other neurodegenerative disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SynuCa Therapeutics Comparables
Compare SynuCa Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neurodon, LLC | 84% | |
| Teitur Trophics | 71% | |
| Mission Therapeutics | 70% |
For institutional investors. Book with your work email.
SynuCa Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Mar 2, 2026 | ||||
| Accelerator | Feb 25, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
SynuCa Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioInnovation Institute | Follow-on Offering, Accelerator |
| NOME | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 2, 2026
$1.49M round led by BioInnovation Institute.
- Feb 25, 2025
$520K raised from BioInnovation Institute and NOME.
For institutional investors. Book with your work email.
SynuCa Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SynuCa Therapeutics's valuation, stock price, and market status.
Is SynuCa Therapeutics a public or private company?
SynuCa Therapeutics is a private company.
What is the current stock price of SynuCa Therapeutics?
SynuCa Therapeutics is a private company, so its shares have no public market price. Caplight tracks SynuCa Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SynuCa Therapeutics worth (valuation)?
Valuation information for SynuCa Therapeutics is not publicly available.
Can I buy SynuCa Therapeutics stock?
SynuCa Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SynuCa Therapeutics's last funding round?
SynuCa Therapeutics's most recent funding round was Follow-on Offering on March 2, 2026.
Who are the main investors in SynuCa Therapeutics?
Key investors in SynuCa Therapeutics include BioInnovation Institute, NOME.
Will SynuCa Therapeutics IPO soon?
No public IPO plans have been announced for SynuCa Therapeutics.
How can I track SynuCa Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in SynuCa Therapeutics's shares on secondary markets.